Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial (Q33167710)

23 July 2017

title

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial (English)

1 reference

multicenter clinical trial

23 July 2017

main subject

0 references

1 reference

1 reference

6

Paul G Richardson

1 reference

23 July 2017

Andrew J Yee

1

1 reference

23 July 2017

William I Bensinger

2

1 reference

23 July 2017

Jeffrey G Supko

3

1 reference

23 July 2017

Peter M Voorhees

4

1 reference

23 July 2017

Jesus G Berdeja

5

1 reference

23 July 2017

Edward N Libby

7

1 reference

23 July 2017

Ellen E Wallace

8

1 reference

23 July 2017

Nicole E Birrer

9

1 reference

23 July 2017

Jill N Burke

10

1 reference

23 July 2017

David L Tamang

11

1 reference

23 July 2017

Min Yang

12

1 reference

23 July 2017

Simon S Jones

13

1 reference

23 July 2017

Catherine A Wheeler

14

1 reference

23 July 2017

Robert J Markelewicz

15

1 reference

23 July 2017

Noopur S Raje

16

1 reference

23 July 2017

publication date

16 September 2016

1 reference

Lancet Oncology Commission

23 July 2017

published in

1 reference

23 July 2017

volume

17

1 reference

23 July 2017

issue

11

1 reference

23 July 2017

page(s)

1569-1578

1 reference

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Histone deacetylase inhibitors: overview and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930375-8

7 January 2021

10.1016/S1470-2045(16)30375-8

Identifiers

DOI

1 reference

23 July 2017

1 reference